Axiom Bio

📍 San Francisco, United States🗓 Founded 2024👥 26 employees💰 Last funded Oct 2024
Biotechnology Research🌐 axi.om
Website LinkedIn
Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axioms AI models offer higher accuracy than advanced in vitro systems like 3d spheroids, deep mechanistic understanding which untangles mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more, and precise risk assessment for any molecule at relevant clinical dosage and clinical exposure levels. Our models remove the need for costly physical experiments, giving more accurate and cheaper toxicity assessments, and empowering scientists to make better-informed decisions and bring safer drugs to the clinic.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2024
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2023–2024 · investors recorded per year
2023120242
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Axiom Bio?
Axiom Bio has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Axiom Bio last raise funding?
The most recent investment in Axiom Bio recorded on gritt.io was in October 2024.
When was Axiom Bio founded?
Axiom Bio was founded in 2024.
What industry is Axiom Bio in?
Axiom Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Axiom Bio based?
Axiom Bio is headquartered in San Francisco, United States.